Gossamer Bio Inc (GOSS)
0.7333
-0.05
(-6.07%)
USD |
NASDAQ |
May 07, 16:00
0.7333
0.00 (0.00%)
After-Hours: 20:00
Gossamer Bio Research and Development Expense (Quarterly): 29.97M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 29.97M |
| September 30, 2023 | 31.20M |
| June 30, 2023 | 36.31M |
| March 31, 2023 | 37.80M |
| December 31, 2022 | 41.51M |
| September 30, 2022 | 44.51M |
| June 30, 2022 | 42.58M |
| March 31, 2022 | 42.32M |
| December 31, 2021 | 40.93M |
| September 30, 2021 | 43.19M |
| June 30, 2021 | 44.32M |
| March 31, 2021 | 41.83M |
| December 31, 2020 | 38.91M |
| Date | Value |
|---|---|
| September 30, 2020 | 41.85M |
| June 30, 2020 | 38.68M |
| March 31, 2020 | 41.41M |
| December 31, 2019 | 42.60M |
| September 30, 2019 | 40.15M |
| June 30, 2019 | 35.68M |
| March 31, 2019 | 24.98M |
| December 31, 2018 | 25.87M |
| September 30, 2018 | 18.86M |
| June 30, 2018 | 7.93M |
| March 31, 2018 | 2.624M |
| December 31, 2017 | 0.675M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
29.97M
Minimum
Dec 2023
44.51M
Maximum
Sep 2022
39.78M
Average
41.41M
Median
Mar 2020
Research and Development Expense (Quarterly) Benchmarks
| Amicus Therapeutics Inc | 35.03M |
| TG Therapeutics Inc | 32.72M |
| Replimune Group Inc | 42.85M |
| 89bio Inc | 33.59M |
| Moderna Inc | 1.063B |